Merck Expands Cancer Drug Portfolio with $3.3 Billion Agreement in China
2 months ago
In a significant move to bolster its cancer treatment offerings, Merck & Co. has secured a lucrative agreement with a Chinese biotech company, attaching itself to a compelling late-stage cancer therapy. The deal, which could reach a staggering $3.3 billion, is centered around the promising drug known as sugemalimab, known for its potential effectiveness against various tumors.
Continue readingAstraZeneca Forecasts Increased Profit and Sales Driven by Cancer Drug Success
2 months ago
AstraZeneca, the renowned biopharmaceutical company, has announced optimistic financial projections, attributing its anticipated growth to a surge in sales from its cancer treatment portfolio. The company’s latest guidance reflects an expected rise in profit as well as sales, bolstered significantly by its innovative oncology drugs.
Continue reading